Report Overview

The Hematologic Drug market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Anaemia has long been recognised as a major public health problem among young children and women of child-bearing age in lower- and middle-income countries and is an indicator of poor nutrition and health status.Approximately one in four Kenyan children aged <15 years were described as anaemic, including 12% with WHO-defined moderate anaemia and 1% were severely anaemic. In a study conducted to determine prevalence of anaemia in pregnant women in Kenya, it was found that 40% were anaemic, of which 62.5% were mildly anaemic and 37.5 % were moderately anaemic. Hookworm infestation, malaria and HIV infections contribute immensely to anaemia cases reported in pregnant women. Sickle cell disease (SCD) is a genetic disorder that affects the haemoglobin (Hb) molecule. As per the estimate, 12-15 million SCD patients are living in Africa. According to the American Society of Haematology, the prevalence of SCD is anticipated to increase by 30% by 2050.



Market Drivers

The market is majorly driven by the rising burden of Hematologic diseases. Sickle cell disease (SCD) is the most common hemoglobinopathy encountered in Kenya. In the western part of the country, about 4.5% of children are born with SCD, and 18% of children are born with sickle cell trait. The rising prevalence of sickle Cell Disease in Africa is one of the major factors to augment growth of the market.

The increasing incidence of Blood Cancers in Kenya is also driving the growth of the market. Cancer in Africa is an emerging health problem. Chronic Leukaemia accounts for 5.4% of all the cancer cases in the country.

Development of new products by pharmaceutical companies has led to growth in the sickle cell Drug market. The New drug by Novartis AG (Adakveo) has been approved by FDA as treatment in sickle cell disease.

However, the high cost of treatment imposes significant financial burden on patients, lack of donors and postponement of blood transfusion procedures during the pandemic are among the restraining factors for growth in the hematologic drug market.